Dose Insider / Glossary / Exenatide

ExenatideWhat it is, where it came from and how Byetta is taken

Updated November 20, 2026 · 3 min read · BYETTA prescribing information, DailyMed, September 2025

Exenatide is a GLP-1 receptor agonist first approved in the United States in 2005, under the brand name Byetta, to improve blood sugar control in adults with type 2 diabetes. Its approval came years before those of liraglutide in 2010 and semaglutide in 2017.

−0.910 micrograms twice a day, fall in HbA1c at week 24
Fall in HbA1c at week 24Byetta on its own, percentage points10 micrograms twice a day−0.95 micrograms twice a day−0.7Placebo−0.2Fall in HbA1c at week 24Byetta on its own, percentage points10 micrograms twice a day−0.95 micrograms twice a day−0.7Placebo−0.2

53% on the higher dose reached an HbA1c under 7%, against 38% on placebo.

On this page

It is a synthetic peptide first identified in a lizard, the Gila monster, and it is injected twice a day before meals.1,2,3

Where it came from

The label describes exenatide as a synthetic peptide that was originally identified in the lizard Heloderma suspectum, the Gila monster. It is a chain of 39 amino acids with a molecular weight of 4,186.6 daltons, close to semaglutide's 4,113.58.1,3

It still does not last long. The mean terminal half-life of exenatide is 2.4 hours, and it is cleared mainly through the kidneys.1 That is why Byetta is given twice a day around meals, while liraglutide, with a half-life of about 13 hours, is given once a day and semaglutide, with a half-life of about 1 week, once a week.2,3

How Byetta is taken

Byetta starts at 5 micrograms injected under the skin twice a day, at any time within the 60 minutes before the morning and evening meals, or before the two main meals of the day at least about 6 hours apart. It is not to be injected after a meal. Depending on the response, the dose can rise to 10 micrograms twice a day, which the label recommends after 1 month to lower the risk of stomach and gut side effects.1

Its dose is counted in micrograms, thousandths of a milligram, and each injection is tied to a meal. Our page on timing a weekly GLP-1 shot shows how much more freedom the weekly medicines allow.

What it did in trials

In the label's 24-week trial of Byetta on its own, HbA1c started at about 7.8% to 7.9%. It fell by 0.7 points on 5 micrograms and 0.9 on 10 micrograms twice a day, against 0.2 on placebo. An HbA1c under 7% was reached by 48% and 53%, against 38% on placebo, and weight fell by 2.7 and 2.9 kg against 1.5 kg.1

Those changes are smaller than in the trials of the weekly medicines that followed. In the Ozempic trial of the drug on its own, for example, HbA1c fell by 1.6 points on 1 mg, from a starting point near 8%.3 The trials enrolled different people at different times and were not run against each other.

Side effects and warnings

When Byetta was added to metformin or a sulfonylurea in three 30-week trials, nausea was reported by 44% against 18% on placebo, vomiting by 13% against 4% and diarrhea by 13% against 6%. The label notes that nausea usually decreases over time.1

Its warnings cover acute pancreatitis, including fatal cases, low blood sugar when combined with insulin or a sulfonylurea, kidney injury from fluid loss, severe stomach and gut reactions, antibodies to exenatide and allergic reactions.1 Unlike the labels of the weekly GLP-1 medicines, the Byetta label carries no boxed warning about thyroid C-cell tumors.1,3

Exenatide in eight lines

FactByetta
Active ingredientExenatide
First U.S. approval2005
OriginPeptide first found in the Gila monster
How oftenTwice a day, before meals
Doses5 micrograms to start, then 10
Half-life2.4 hours
Approved forType 2 diabetes, adults
Thyroid boxed warningNo

BYETTA prescribing information, DailyMed version of September 8, 2025.1

Liraglutide and dulaglutide are the next generations of the class, and semaglutide and tirzepatide the newest. Our page on Ozempic and Mounjaro compares the two most used weekly diabetes injections.

Sources

  1. BYETTA (exenatide) injection prescribing information. AstraZeneca; DailyMed, U.S. National Library of Medicine, version published September 8, 2025; sections 1, 2, 5, 6.1, 11, 12 and 14. dailymed.nlm.nih.gov
  2. SAXENDA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, version published June 15, 2026; boxed warning and section 12.3. dailymed.nlm.nih.gov
  3. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; boxed warning and sections 11, 12.3 and 14; Initial U.S. Approval. accessdata.fda.gov

Related analyses

Log each dose and meal time, and see your day on one screen.

Open Dose Insider